precision biosciences, inc. is a biotechnology company located in durham, north carolina, united states.
Company profile
Ticker
DTIL
Exchange
Website
CEO
Matthew Kane
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Precision PlantSciences, Inc. • Precision BioSciences UK Limited ...
DTIL stock data
Latest filings (excl ownership)
8-K
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
16 Apr 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
27 Mar 24
424B5
Prospectus supplement for primary offering
1 Mar 24
8-K
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants
1 Mar 24
FWP
Free writing prospectus
1 Mar 24
424B5
Prospectus supplement for primary offering
29 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
13 Feb 24
8-K
Departure of Directors or Certain Officers
23 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
19 Jan 24
Latest ownership filings
4
J. JEFFERSON SMITH
22 Apr 24
4
Michael Amoroso
22 Apr 24
4
Dario Scimeca
22 Apr 24
4
John Alexander Kelly
22 Apr 24
SC 13G
Aquilo Capital Management, LLC
18 Mar 24
SC 13G
PERCEPTIVE ADVISORS LLC
14 Mar 24
SC 13G
JANUS HENDERSON GROUP PLC
11 Mar 24
SC 13G/A
GREAT POINT PARTNERS LLC
14 Feb 24
SC 13G/A
Capital World Investors
12 Feb 24
SC 13G
TANG CAPITAL PARTNERS LP
5 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 122.23 mm | 122.23 mm | 122.23 mm | 122.23 mm | 122.23 mm | 122.23 mm |
Cash burn (monthly) | 5.19 mm | 7.49 mm | 4.12 mm | 8.25 mm | 7.70 mm | 8.13 mm |
Cash used (since last report) | 35.46 mm | 51.17 mm | 28.17 mm | 56.39 mm | 52.62 mm | 55.56 mm |
Cash remaining | 86.77 mm | 71.06 mm | 94.06 mm | 65.84 mm | 69.61 mm | 66.67 mm |
Runway (months of cash) | 16.7 | 9.5 | 22.8 | 8.0 | 9.0 | 8.2 |
Institutional ownership, Q4 2023
13F holders | Current |
---|---|
Total holders | 12 |
Opened positions | 0 |
Closed positions | 66 |
Increased positions | 2 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 280.00 mm |
Total shares | 19.38 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Novartis Pharma | 12.41 mm | $15.01 mm |
LLY Lilly(Eli) & Co | 3.76 mm | $0.00 |
venBio Global Strategic Fund | 2.54 mm | $21.05 mm |
Redwood Wealth Management | 212.49 k | $77.56 mm |
Harbor Capital Advisors | 149.73 k | $54.65 mm |
Allworth Financial | 143.07 k | $52.22 mm |
First Citizens Bank & Trust | 85.00 k | $31.03 mm |
Foster Victor Wealth Advisors | 46.18 k | $18.38 mm |
HBK Sorce Advisory | 13.50 k | $4.93 mm |
626 Financial | 13.17 k | $4.81 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Apr 24 | J. Jefferson Smith | RSU Common Stock | Grant | Acquire A | No | No | 0 | 31,343 | 0.00 | 31,343 |
18 Apr 24 | Michael Amoroso | RSU Common Stock | Grant | Acquire A | No | No | 0 | 111,217 | 0.00 | 111,217 |
18 Apr 24 | Scimeca Dario | RSU Common Stock | Grant | Acquire A | No | No | 0 | 25,277 | 0.00 | 25,277 |
18 Apr 24 | John Alexander Kelly | RSU Common Stock | Grant | Acquire A | No | No | 0 | 41,705 | 0.00 | 41,705 |
23 Jan 24 | J. Jefferson Smith | Common Stock | Sell | Dispose S | No | No | 0.37 | 28,000 | 10.36 k | 1,987,269 |
20 Jan 24 | J. Jefferson Smith | Common Stock | Option exercise | Acquire M | No | No | 0 | 75,015 | 0.00 | 2,015,269 |
20 Jan 24 | J. Jefferson Smith | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 75,015 | 0.00 | 149,985 |
News
HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target
17 Apr 24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
17 Apr 24
Precision BioSciences Announces Return Of Programs And Conclusion Of Collaboration With Prevail Therapeutics
16 Apr 24
iECURE Announces FDA Clearance Of IND Application For ECUR-506 To Initiate OTC-HOPE Trial For Treatment Of Neonatal Onset Ornithine Transcarbamylase Deficiency In The U.S.; NOTE: iECURE Has Licensed The ARCUS Nuclease For ECUR-506 From Precision BioSciences
4 Apr 24
Precision BioSciences Q4 GAAP EPS $(4.06) May Not Be Comparable To $(2.05) Estimate, Sales $7.04M Miss $12.48M Estimate
27 Mar 24
Press releases
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
16 Apr 24
iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.
4 Apr 24
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
27 Mar 24
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
20 Mar 24
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
6 Mar 24